<DOC>
	<DOCNO>NCT00005990</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness R115777 plus topotecan treating patient advance solid tumor .</brief_summary>
	<brief_title>R115777 Plus Topotecan Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine dose-limiting toxic effect R115777 topotecan patient advance solid tumor . - Determine maximum tolerate dose regimen patient . - Determine pharmacokinetic profile topotecan alone combination R115777 patient . - Measure inhibition ras-farnesylation topo-1 inhibition peripheral blood mononuclear cell patient treat regimen . - Determine activity treatment patient . OUTLINE : This dose-escalation , multicenter study . Patients receive oral R115777 twice daily day 2-21 ( first course R115777 begin day 3 ) topotecan IV continuously day 1-21 . Treatment continue every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos R115777 topotecan maximum tolerate dose ( MTD ) determine . The MTD define dose 2 3 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 18-24 patient accrue study .</detailed_description>
	<mesh_term>Tipifarnib</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced solid tumor amenable standard curative therapy PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : At least 6 month Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL SGOT great 5 time upper limit normal ( ULN ) Alkaline phosphatase great 5 time ULN No significant hepatic dysfunction would preclude study Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 50 mL/min Cardiovascular : No significant cardiovascular dysfunction would preclude study Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malabsorption syndrome , partial complete bowel obstruction , disease significantly affect gastrointestinal function , major resection stomach proximal small bowel At least 1 week since prior active infection require systemic medical therapy No significant organ system dysfunction ( neurologic , endocrine ) would preclude study No dementia alter mental status would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No 3 prior chemotherapy regimen At least 4 week since prior chemotherapy recover Endocrine therapy : Not specify Radiotherapy : No 25 % bone marrow volume irradiate No prior pelvic radiation At least 4 week since prior radiotherapy recover Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>